Your shopping cart is currently empty

Dopexamine hydrochloride (FPL60278AR) is a β2-adrenergic receptor agonist. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $38 | In Stock | In Stock | |
| 5 mg | $60 | In Stock | In Stock | |
| 10 mg | $93 | In Stock | In Stock | |
| 25 mg | $218 | In Stock | In Stock | |
| 50 mg | $372 | In Stock | In Stock | |
| 100 mg | $633 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $66 | In Stock | In Stock |
| Description | Dopexamine hydrochloride (FPL60278AR) is a β2-adrenergic receptor agonist. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. |
| In vitro | Dopexamine, a dopamine analogue, stimulates β-adrenergic as well as dopamine 1 and 2 receptors, offering vasodilatory effects. It effectively mitigates the systemic inflammatory response triggered by endotoxin, including the release of cytokines, the expression of endothelial adhesion molecules, and oxidative stress, without significantly affecting systemic hemodynamics, such as blood pressure or stroke volume. Additionally, dopexamine possesses agonist activity at β2 and dopaminergic receptors, and at dosages that do not impact global hemodynamics or regional microvascular flow, it can diminish tissue leukocyte infiltration and confer protection against organ damage. |
| Synonyms | FPL60278AR |
| Molecular Weight | 429.42 |
| Formula | C22H34Cl2N2O2 |
| Cas No. | 86484-91-5 |
| Smiles | Cl.Cl.Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 10 mg/mL (23.29 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.33 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.